Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO

Kala Pharmaceuticals, Inc. KALA, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking place on October 25, 2018. Data from a Phase 3 clinical trial conducted with KPI-121 0.25% for the short-term treatment of dry eye disease and data from the Phase 3 clinical trials conducted with INVELTYS™ (loteprednol etabonate ophthalmic suspension) 1%, a twice-a-day topical ocular corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery, will also be presented at the 2018 American Academy of Ophthalmology (AAO) annual meeting taking place October 27-30, 2018 in Chicago, IL.

Details of the presentations are as follows:

Meeting: OIS@AAO

Session title: Company Showcase 2

Date: Thursday, October 25, 2018

Time: 10:41 - 10:47 AM CT

Location: Marriott Marquis Chicago

Presenter: Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals

Meeting: AAO

Title: KPI-121 0.25% for Short-term Treatment of Dry Eye Disease: Results of a Multicenter Randomized Phase 3 Trial (STRIDE 1)

Date: Sunday, October 28, 2018

Time: 12:45 - 1:45 PM CT

Location: McCormick Place, Hall A

Presenter: Preeya Gupta, M.D., Associate Professor of Ophthalmology, Duke University School of Medicine

Meeting: AAO

Title: Phase 3 Results for KPI-121 1% Ophthalmic Suspension Dosed BID Versus Placebo for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Date: Monday, October 29, 2018

Time: 12:45 - 1:45 PM CT

Location: McCormick Place, Hall A

Presenter: John Sheppard, M.D., MMSc, Program Director for Ophthalmology Residency Research, Clinical Director for the Thomas R. Lee Center for Ocular Pharmacology, and Professor of Ophthalmology, Microbiology & Molecular Biology, Eastern Virginia Medical School; Medical Director of the Lions Medical Eye Bank

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY^TM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. In preclinical studies, MPPs increased drug delivery into ocular tissues more than three-fold by facilitating penetration through the tear film mucus. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYS^TM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005260/en/